Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer.

Alaunos Therapeutics

Status and phase: Terminated; Phase 2

Conditions: Breast Cancer Nos Metastatic Recurrent

Treatments: Drug: Palifosfamide; Genetic: Ad-RTS-hIL-12 and Veledimex

Study type: Interventional

Funder types: Industry

Identifiers

NCT01703754

ATI001-201

Details and patient eligibility

About

Phase II, randomized, safety and efficacy study in recurrent/metastatic breast cancer with accessible lesions.

Primary End point is rate of Progression Free Survival (PFS) at the 16 week treatment time point. Hypothesis: Adenoviral vector (Ad-RTS-hIL-12) alone and in combination with chemotherapy (palifosfamide) is safe and efficacious.

Full description

Multicenter, open-label, randomized study evaluating the safety and efficacy of INXN-1001 (veledimex) and INXN-2001 (Ad-RTS-hIL-12) alone and in combination with palifosfamide.

Part 1 is the safety run-in where a safety assessment will be made after 1 cycle of therapy.

Part 2, eligible subjects will be randomly assigned to active treatment Arms A or C.

Once the monotherapy (Arm A) is determined to be safe and tolerable, Part 1 combination therapy (Arm C) will begin.

Subjects should receive six cycles of study treatment, in the absence of meeting withdrawal criteria.

Enrollment: 12 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Males or females ≥ 18 years of age

2. Histologically or cytologically confirmed adenocarcinoma of the breast, either locally recurrent or metastatic disease with injectable lesions, for which no proven curative therapy exists.

3. Failed or progressed on at least 1 prior systemic chemotherapy regimen ± biologic/experimental therapy (if first-line therapy, failure or progression during the first 30 days).

4. Resolution of all treatment-related toxicities to Grade 1 severity or lower, except for stable sensory neuropathy ≤ Grade 2 and alopecia.

5. A minimum of 2 lesion(s) assessed by imaging using mRECIST v1.1.

6. Eastern Cooperative Oncology Group performance status 0, 1, 2

7. Male and female subjects must agree to use a highly reliable method of birth control.

8. Adequate bone marrow reserve as indicated by:

   1. Absolute neutrophil count > 1500/μL (without use of growth factors within 7 days)
   2. Absolute lymphocyte count > 700/μL (without use of growth factors within 7 days)
   3. Platelet count > 100,000/mm3 (without transfusion in prior 7 days)
   4. Hemoglobin > 9.0 g/dL (without transfusion in prior 7 days)

9. Estimated glomerular filtration rate using the Modification of Diet in Renal Disease equation: eGFR ≥ 60 mL/min/1.73 m2

10. Adequate liver function as evidenced by the following:

    1. Bilirubin ≤ 1.5 times the upper limits of normal (ULN)
    2. Alanine aminotransferase (ALT), and aspartate aminotransferase (AST) ≤ 2.5×ULN, in the case of liver metastases ≤ 5×ULN

Exclusion criteria

1. Subjects with human epidermal growth factor receptor 2 (HER2)/neu-positive (immunohistochemistry [IHC]) 3+ or fluorescence in situ hybridization-amplified) breast tumors who are eligible for, but who have not received HER2-targeted therapy (eg, trastuzumab)

2. Concomitant anticancer therapies

3. Prior therapies discontinuation periods:

   1. Radiation within 3 weeks of enrollment
   2. Chemotherapy within 4 weeks of enrollment
   3. Nitrosoureas within 6 weeks of enrollment
   4. Biologic therapy and/or immunomodulatory therapy, checkpoint inhibitors within 6 weeks of enrollment
   5. No washout period is required for endocrine therapy

4. Radiation therapy encompassing >25% of bone marrow

5. History of bone marrow or stem cell transplantation

6. Any congenital or acquired condition leading to inability to generate an immune response

7. Immunosuppressive therapy:

   1. Systemic immunosuppressive drugs including corticosteroids (prednisone equivalent >10 mg/day)
   2. Immune suppression/requiring immunosuppressive drugs, including organ allografts
   3. Active autoimmune disease requiring the equivalent of >10 mg/day of prednisone

8. Major surgery within 4 weeks of study treatment

9. History of prior malignancy, unless the prior malignancy was diagnosed and definitively treated ≥5 years previously with no subsequent evidence of recurrence

10. Subjects with brain or subdural metastases, unless local therapy has completed and corticosteroids have been discontinued for this indication for ≥4 weeks before starting study treatment.

11. Any medications that induce, inhibit, or are substrates of cytochrome P450 (CYP450) 3A4 within 7 days prior to the first dose of study drug

12. Subjects with meningeal carcinomatosis

13. Known significant hypersensitivity to study drugs or excipients

14. History of malabsorption syndrome or other condition that would interfere with enteral absorption

15. International Normalized Ratio (INR) and activated partial thromboplastin time [PTT] <1.5 x ULN, if not therapeutically anticoagulated.

16. New York Heart Association (NYHA) Class II or greater congestive heart failure OR active ventricular arrhythmia requiring medication

17. Any other unstable or clinically significant concurrent medical condition

18. Localized infection at site of injectable lesion(s) requiring antiinfective therapy within 2 weeks of the first dose of study drug.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

12 participants in 2 patient groups

Ad-RTS-hIL-12 and veledimex

Experimental group

Description:

Experimental study drug monotherapy arm (A)

Treatment:

Genetic: Ad-RTS-hIL-12 and Veledimex

Ad-RTS-hIL-12 and Palifosfamide

Experimental group

Description:

Study drug combination therapy arm (C)

Treatment:

Genetic: Ad-RTS-hIL-12 and Veledimex

Drug: Palifosfamide